Drugs / CD20 CAR-T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03576807 | Apr 2018 → Apr 2019 | B-cell non-Hodgkin lymphoma | Xin Wang | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03207178 | Mar 2017 → Feb 2019 | B-cell neoplasm | Shanghai Longyao Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD20 CAR-T cells | “Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.” NCT03207178 ↗ |
| Action | Deplete | “Assess the killing ability of CD20-CART cell agents to tumor cells in vitro” NCT03576807 ↗ |
| Modality | Cell therapy | “Both CD19-targeting CAR T Cells and CD20-targeting CAR T Cells can be used as adoptive cellular immunotherapies for B-cell lymphomas.” NCT03207178 ↗ |
| Route | Intravenous | “will be administered by IV infusions” NCT03576807 ↗ |